vs
COMSCORE, INC.（SCOR）与Tarsus Pharmaceuticals, Inc.（TARS）财务数据对比。点击上方公司名可切换其他公司
Tarsus Pharmaceuticals, Inc.的季度营收约是COMSCORE, INC.的1.6倍（$151.7M vs $93.5M），COMSCORE, INC.净利率更高（3.2% vs -5.5%，领先8.8%），Tarsus Pharmaceuticals, Inc.同比增速更快（128.4% vs -1.5%），Tarsus Pharmaceuticals, Inc.自由现金流更多（$13.0M vs $2.9M），过去两年Tarsus Pharmaceuticals, Inc.的营收复合增速更高（134.4% vs 3.8%）
Comscore是总部设于美国的全球媒体测量与分析企业，为企业、广告代理商、品牌营销方及媒体出版方提供专业营销数据与分析服务，在全球媒体行业和营销领域拥有广泛影响力。
Tarsus Pharmaceuticals是一家处于后期临床阶段的生物制药公司，专注于眼科、皮肤科等专科领域创新疗法的研发和商业化，主打产品针对蠕形螨睑缘炎、玫瑰痤疮等未被充分诊断的常见病症，核心市场为美国。
SCOR vs TARS — 直观对比
营收规模更大
TARS
是对方的1.6倍
$93.5M
营收增速更快
TARS
高出129.9%
-1.5%
净利率更高
SCOR
高出8.8%
-5.5%
自由现金流更多
TARS
多$10.0M
$2.9M
两年增速更快
TARS
近两年复合增速
3.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $93.5M | $151.7M |
| 净利润 | $3.0M | $-8.4M |
| 毛利率 | 41.0% | — |
| 营业利润率 | 7.0% | -5.3% |
| 净利率 | 3.2% | -5.5% |
| 营收同比 | -1.5% | 128.4% |
| 净利润同比 | -3.7% | 63.8% |
| 每股收益（稀释后） | $9.50 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SCORTARS
| Q4 25 | $93.5M | $151.7M | ||
| Q3 25 | $88.9M | $118.7M | ||
| Q2 25 | $89.4M | $102.7M | ||
| Q1 25 | $85.7M | $78.3M | ||
| Q4 24 | $94.9M | $66.4M | ||
| Q3 24 | $88.5M | $48.1M | ||
| Q2 24 | $85.8M | $40.8M | ||
| Q1 24 | $86.8M | $27.6M |
净利润SCORTARS
| Q4 25 | $3.0M | $-8.4M | ||
| Q3 25 | $453.0K | $-12.6M | ||
| Q2 25 | $-9.5M | $-20.3M | ||
| Q1 25 | $-4.0M | $-25.1M | ||
| Q4 24 | $3.1M | $-23.1M | ||
| Q3 24 | $-60.6M | $-23.4M | ||
| Q2 24 | $-1.7M | $-33.3M | ||
| Q1 24 | $-1.1M | $-35.7M |
毛利率SCORTARS
| Q4 25 | 41.0% | — | ||
| Q3 25 | 40.6% | — | ||
| Q2 25 | 40.6% | — | ||
| Q1 25 | 39.6% | — | ||
| Q4 24 | 42.4% | — | ||
| Q3 24 | 41.2% | — | ||
| Q2 24 | 39.5% | — | ||
| Q1 24 | 42.3% | — |
营业利润率SCORTARS
| Q4 25 | 7.0% | -5.3% | ||
| Q3 25 | 1.9% | -12.2% | ||
| Q2 25 | -1.9% | -21.6% | ||
| Q1 25 | -2.4% | -33.5% | ||
| Q4 24 | 4.1% | -36.8% | ||
| Q3 24 | -67.4% | -52.3% | ||
| Q2 24 | -2.2% | -81.6% | ||
| Q1 24 | -2.2% | -136.5% |
净利率SCORTARS
| Q4 25 | 3.2% | -5.5% | ||
| Q3 25 | 0.5% | -10.6% | ||
| Q2 25 | -10.6% | -19.8% | ||
| Q1 25 | -4.7% | -32.1% | ||
| Q4 24 | 3.3% | -34.8% | ||
| Q3 24 | -68.5% | -48.7% | ||
| Q2 24 | -2.0% | -81.6% | ||
| Q1 24 | -1.2% | -129.4% |
每股收益（稀释后）SCORTARS
| Q4 25 | $9.50 | $-0.17 | ||
| Q3 25 | $-0.86 | $-0.30 | ||
| Q2 25 | $-2.73 | $-0.48 | ||
| Q1 25 | $-1.66 | $-0.64 | ||
| Q4 24 | $-0.47 | $-0.57 | ||
| Q3 24 | $-12.79 | $-0.61 | ||
| Q2 24 | $-1.19 | $-0.88 | ||
| Q1 24 | $-1.08 | $-1.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $23.6M | $417.3M |
| 总债务越低越好 | $41.5M | $72.4M |
| 股东权益账面价值 | $111.4M | $343.4M |
| 总资产 | $407.7M | $562.2M |
| 负债/权益比越低杠杆越低 | 0.37× | 0.21× |
8季度趋势，按日历期对齐
现金及短期投资SCORTARS
| Q4 25 | $23.6M | $417.3M | ||
| Q3 25 | $26.7M | $401.8M | ||
| Q2 25 | $26.0M | $381.1M | ||
| Q1 25 | $31.0M | $407.9M | ||
| Q4 24 | $29.9M | $291.4M | ||
| Q3 24 | $20.0M | $317.0M | ||
| Q2 24 | $14.7M | $323.6M | ||
| Q1 24 | $18.7M | $298.5M |
总债务SCORTARS
| Q4 25 | $41.5M | $72.4M | ||
| Q3 25 | $41.4M | $72.3M | ||
| Q2 25 | $41.3M | $72.1M | ||
| Q1 25 | $41.3M | $72.0M | ||
| Q4 24 | $41.2M | $71.8M | ||
| Q3 24 | — | $71.7M | ||
| Q2 24 | — | $71.6M | ||
| Q1 24 | — | $29.9M |
股东权益SCORTARS
| Q4 25 | $111.4M | $343.4M | ||
| Q3 25 | $-26.3M | $335.1M | ||
| Q2 25 | $-21.7M | $332.6M | ||
| Q1 25 | $-13.5M | $342.5M | ||
| Q4 24 | $-8.3M | $224.5M | ||
| Q3 24 | $-2.7M | $237.5M | ||
| Q2 24 | $45.8M | $252.2M | ||
| Q1 24 | $51.4M | $275.2M |
总资产SCORTARS
| Q4 25 | $407.7M | $562.2M | ||
| Q3 25 | $406.9M | $534.6M | ||
| Q2 25 | $415.9M | $495.0M | ||
| Q1 25 | $421.5M | $500.8M | ||
| Q4 24 | $430.2M | $377.0M | ||
| Q3 24 | $412.5M | $376.3M | ||
| Q2 24 | $474.1M | $376.8M | ||
| Q1 24 | $477.7M | $349.3M |
负债/权益比SCORTARS
| Q4 25 | 0.37× | 0.21× | ||
| Q3 25 | — | 0.22× | ||
| Q2 25 | — | 0.22× | ||
| Q1 25 | — | 0.21× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.30× | ||
| Q2 24 | — | 0.28× | ||
| Q1 24 | — | 0.11× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.2M | $19.3M |
| 自由现金流经营现金流 - 资本支出 | $2.9M | $13.0M |
| 自由现金流率自由现金流/营收 | 3.1% | 8.6% |
| 资本支出强度资本支出/营收 | 0.3% | 4.2% |
| 现金转化率经营现金流/净利润 | 1.07× | — |
| 过去12个月自由现金流最近4个季度 | $21.8M | $-22.3M |
8季度趋势，按日历期对齐
经营现金流SCORTARS
| Q4 25 | $3.2M | $19.3M | ||
| Q3 25 | $9.5M | $18.3M | ||
| Q2 25 | $932.0K | $-29.4M | ||
| Q1 25 | $9.1M | $-20.7M | ||
| Q4 24 | $-10.0M | $-22.2M | ||
| Q3 24 | $12.5M | $-8.7M | ||
| Q2 24 | $8.7M | $-14.4M | ||
| Q1 24 | $6.9M | $-37.8M |
自由现金流SCORTARS
| Q4 25 | $2.9M | $13.0M | ||
| Q3 25 | $9.4M | $16.3M | ||
| Q2 25 | $787.0K | $-30.4M | ||
| Q1 25 | $8.7M | $-21.2M | ||
| Q4 24 | $-10.3M | $-22.3M | ||
| Q3 24 | $12.4M | $-8.9M | ||
| Q2 24 | $8.5M | $-15.4M | ||
| Q1 24 | $6.6M | $-38.0M |
自由现金流率SCORTARS
| Q4 25 | 3.1% | 8.6% | ||
| Q3 25 | 10.5% | 13.8% | ||
| Q2 25 | 0.9% | -29.6% | ||
| Q1 25 | 10.1% | -27.1% | ||
| Q4 24 | -10.8% | -33.5% | ||
| Q3 24 | 14.0% | -18.6% | ||
| Q2 24 | 10.0% | -37.8% | ||
| Q1 24 | 7.6% | -137.5% |
资本支出强度SCORTARS
| Q4 25 | 0.3% | 4.2% | ||
| Q3 25 | 0.1% | 1.6% | ||
| Q2 25 | 0.2% | 1.0% | ||
| Q1 25 | 0.4% | 0.8% | ||
| Q4 24 | 0.2% | 0.1% | ||
| Q3 24 | 0.1% | 0.6% | ||
| Q2 24 | 0.2% | 2.5% | ||
| Q1 24 | 0.3% | 0.6% |
现金转化率SCORTARS
| Q4 25 | 1.07× | — | ||
| Q3 25 | 20.96× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -3.19× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
TARS
暂无分部数据
